Digest Network Come funziona
Network
/
Società
Da
Non verificato

Daiichi Sankyo

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieOncologiaSalute

76 comunicati stampa

Guarda tutti i comunicati
18/12/2025
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
15/12/2025
Industria
Scienza
Farmaceutica
Oncologia
Vetrine/Shopping
Biotecnologia
Medicina - Varie
Salute
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
09/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Oncologia
Scienza
Vetrine/Shopping
Medicina - Varie
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
08/12/2025
Biotecnologia
Farmaceutica
Salute
Industria
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
03/12/2025
Legge/Diritto
Oncologia
Salute
Sanità
Farmaceutica
Cardiologia
Biotecnologia
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
10/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Industria
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
31/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/10/2025
Eventi
Fiere
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/10/2025
Eventi
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0